Ra Pharmaceuticals Inc

Ra Pharmaceuticals — Investor Presentation (June 2018)

23 slides from Ra Pharmaceuticals's investor presentation, Jun 7, 2018

  1. Slide 1: Forward Looking Statements

    Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the safety, efficacy, regulatory and clinical progress and therapeutic potential of our p

  2. Slide 2: Transforming Complement Therapeutics

    3 Transforming Complement Therapeutics Focused on rare hematologic, renal, and neurologic indications RA101495 SC: Convenient, self-administered, subcutaneous C5 inhibitor Phase 2 studies in paroxysmal nocturnal hemoglobinuria (PNH) completed Phase 2 study in generalized myasthenia gravis (gMG) ongo

  3. Slide 3: Opportunities in Complement Inhibition

    Activated by non-self cells Activated by antibody-antigen complexes Activated by pathogen surfaces C5a C3 C1q – C1r – C1s C7, C8, C9 C5b6 Membrane attack complex (MAC) Binds C5 eculizumab RA101495 SC Binds C5 & C5b Proinflammatory cytokine Lectin Pathway Classical Pathway Alternative Pathway C5 C5b

  4. Slide 4: Pipeline Programs

    5 Pipeline Programs DISCOVERY/ RA101495 SC (PNH) Oral Macrocyclic Peptide (Cardiovascular target with a large market opportunity) Orphan Renal Diseases (SC) Ocular/Autoimmune/CNS diseases PRECLINICAL PHASE 1 PHASE 2 C5 Inhibition Franchise RA101495 SC (gMG) Oral Small Molecule Inhibitor RA101495 SC

  5. Slide 5: RA101495 SC – Positioned for Success

    RA101495 SC – Positioned for Success Large mAb (140 kDa) Last Line Long Infusion (~1 hr) High Volume IV (90-120 mL) Exclusive Small Peptide (3 kDa) Earlier use Brief Injection (5-8 sec.) Convenient SC (~0.5 mL) Accessible Today RA101495 SC Rising Expectations for Complement Inhibition 6

  6. Slide 6: Paroxysmal Nocturnal Hemoglobinuria (PNH) – Rare, Life-threatening, C5-Mediated Disease

    8 Paroxysmal Nocturnal Hemoglobinuria (PNH) – Rare, Life-threatening, C5-Mediated Disease1 Estimated 1.3 per million per year newly diagnosed patients2 1. Kanakura Y. Int J Hematol. 2013; 98:406–416. 2. Hill A. Blood. 2006; 108:985. 3. Soliris® [package insert]. Alexion Pharmaceuticals Inc; revised

  7. Slide 7: RA101495 SC PNH Phase 2 – Study Design

    9 RA101495 SC PNH Phase 2 – Study Design Extension Study Cohort B (switch) n=16 D1 Cohort A (naïve) n=10 W6 W12 W2 Inadequate Responders (LDH > 1.5 x ULN) n=3 Review of safety & efficacy Evaluation period for primary efficacy endpoint (change in LDH from baseline to mean of W6-12) Loading dose: 0.3m

  8. Slide 8: RA101495 SC in Treatment Naïve PNH – Rapid, Robust, Sustained Reduction of LDH

    10 RA101495 SC in Treatment Naïve PNH – Rapid, Robust, Sustained Reduction of LDH References: 1.Hillmen et al. N Engl J Med 2006. 2.U.S. FDA/CDER. (2007) BLA 125166 Pharmacometrics Review Eculizumab/Soliris **Weekly eculizumab loading period *Not a head-to-head comparison. **Relative overdosing of e

  9. Slide 9: RA101495 SC in Treatment Naïve PNH – Treatment Satisfaction and Transfusion Improvements

    11 RA101495 SC in Treatment Naïve PNH – Treatment Satisfaction and Transfusion Improvements At final study visit (W12) 50% of treatment naïve, transfusion-dependent patients have been transfusion-free while on RA101495 SC Treatment Satisfaction Score Mean (SE), n=19 Improvements in Transfusion Depen

  10. Slide 10: RA101495 SC PNH Program – Safety and Tolerability

    13 RA101495 SC Phase 2 PNH Program – Safety and Tolerability Cumulative RA101495 SC exposure: Over 700 patient-weeks No dosing interruptions, down-titrations, or discontinuations due to tolerability No meningococcal infections observed No thromboembolic events observed ~100% compliance with once dai

  11. Slide 11: PNH Opportunity – Potential 1st Line Option

    14 PNH Opportunity – Potential 1st Line Option to Treat All Naïve and Most Switch Patients Not Yet Diagnosed: ~60% Newly Diagnosed Per Year: ~10% 40% With EVH (transfusion dependent) 60% Without EVH (transfusion independent and reticulocyte <2xULN) On Treatment: ~30% Prevalence: ~15.9 per million Re

  12. Slide 12: RA101495 SC – Building a Pipeline within a Product

    15 RA101495 SC – Building a Pipeline within a Product aHUS gMG Ph2 Ph1 Development Potential 1st line option to target complement-mediated damage earlier Potential 1st line option to treat all naïve and most switch patients Potential 1st line option to urgently treat acute or progressive TMA PNH Ph2

  13. Slide 13: Generalized Myasthenia Gravis (gMG) – Rare, Debilitating, C5-Mediated Disease

    16 Generalized Myasthenia Gravis (gMG) – Rare, Debilitating, C5-Mediated Disease1 References: 1. Howard JF. Lancet Neurol. 2017;16(12):976-986. 2. Myasthenia Gravis Foundation of America and Howard JF. Reviewed 2015. Available at http://www.myasthenia.org/HealthProfessionals/ 3. Conti-Fine BM. J Cli

  14. Slide 14: RA101495 SC in gMG – Opportunity to Target Complement-Mediated Damage Earlier

    17 RA101495 SC in gMG – Opportunity to Target Complement-Mediated Damage Earlier Thymectomy Steroids Acetylcholinesterase Inhibitor MG Diagnosis Immunosuppressive Therapies IVIg/PLEX (Crises or Chronic) Refractory Soliris (eculizumab) IV RA101495 SC Opportunity IVIg = intravenous immunoglobulin PLEX

  15. Slide 15: RA101495 SC in gMG – Phase 2 Design

    18 RA101495 SC in gMG – Phase 2 Design Design: Randomized, double-blind placebo-controlled multicenter study, 12-week treatment period followed by a long term extension (LTE) study Patient Population: Generalized MG (Myasthenia Gravis Foundation of America class II-IVa) AChR-antibody positive Quanti

  16. Slide 16: RA101495 SC in gMG – Phase 2 Design

    19 RA101495 SC in gMG – Phase 2 Design N=36 Screening and Washout 1:1:1 Randomization 0.3 mg/kg SC Longterm Extension (Active Drug) 0.1 mg/kg SC Placebo Anticipated initial data read-out 1H19 Study Period Long Term Extension 19 Patients Dosed as of June 5, 2018 Primary Efficacy Endpoint: Change in Q

  17. Slide 17: gMG Opportunity – Potential 1st Line Option

    20 gMG Opportunity – Potential 1st Line Option to Treat Complement-Mediated Damage Earlier Controlled: ~40% Uncontrolled: ~40% Last Line: ~20% Patients adequately managed on steroids or Pyridostigmine Patients lacking control despite treatments, including steroids and multiple ISTs. Patients reverti

  18. Slide 18: RA101495 SC – Building a Pipeline within a Product

    21 RA101495 SC – Building a Pipeline within a Product gMG Ph2 Ph1 Development Potential 1st line option to target complement-mediated damage earlier Potential 1st line option to treat all naïve and most switch patients Potential 1st line option to urgently treat acute or progressive TMA PNH Ph2 ANCA

  19. Slide 19: Atypical Hemolytic Uremic Syndrome (aHUS) – Rare, Life-threatening, C5-Mediated Disease

    22 Atypical Hemolytic Uremic Syndrome (aHUS) – Rare, Life-threatening, C5-Mediated Disease Historically, despite management, within 3 years of diagnosis 79% of patients required dialysis, had permanent kidney damage, or died.3 References: 1. Loirat C. Orphanet J Rare Dis. 2011; 6: 60. 2. Hosler GA.

  20. Slide 20: Phase 1b PK Study in Renal Indications

    23 Phase 1b PK Study in Renal Indications Multi-center, Open-label Trial Data Expected Mid-2018 Enrollment Recently Completed 8 patients with severe renal impairment 8 healthy control subjects with normal renal function Each patient receives a single, SC dose of 0.3 mg/kg of RA101495 SC Trial will c

  21. Slide 21: Orally-Available, Small Molecule Inhibitors of C5

    24 Orally-Available, Small Molecule Inhibitors of C5 Serum + HCl Serum* Serum + HCl + Eculizumab Serum + HCl + Compound A Compound A concentration Type III Type I+II SM Inhibits Complement Mediated Hemolysis of Human PNH Type III Erythrocytes in a Dose-Dependent Manner Podium presentation at EHA 23

  22. Slide 22: Transforming Complement Therapeutics

    25 Transforming Complement Therapeutics Focused on rare hematologic, renal, and neurologic indications RA101495 SC: Convenient, self-administered, subcutaneous C5 inhibitor Phase 2 studies in paroxysmal nocturnal hemoglobinuria (PNH) completed Phase 2 study in generalized myasthenia gravis (gMG) ong

  23. Slide 23: Transforming Complement Therapeutics

    Transforming Complement Therapeutics > Focused on rare hematologic, renal, and neurologic indic ns » RA101495 SC: Convenient, self-administered, subcutaneous C5 inhibitor * Phase 2 studies in paroxysmal nocturnal hemoglobinuria (PNH) completed + Phase 2 study in generalized myasthenia gravis (gMG) o

Ra Pharmaceuticals — Investor Presentation (June 2018) on 6ix